Keith Michael Gottesdiener's Net Worth

$38.2 Million

Estimate Recalculated Nov 11, 2024 01:40PM EST

Who is Keith Michael Gottesdiener

Keith Michael Gottesdiener has an estimated net worth of $38.2 Million. This is based on reported shares across multiple companies, which include RHYTHM PHARMACEUTICALS, INC., INTERCEPT PHARMACEUTICALS, INC., and Prime Medicine, Inc..

SEC CIK

Keith Michael Gottesdiener's CIK is 0001615856

Past Insider Trading and Trends

2018 was Keith Michael Gottesdiener's most active year for acquiring shares with 5 total transactions. Keith Michael Gottesdiener's most active month to acquire stocks was the month of April. 2019 was Keith Michael Gottesdiener's most active year for disposing of shares, totalling 14 transactions. Keith Michael Gottesdiener's most active month to dispose stocks was the month of October. 2020 saw Keith Michael Gottesdiener paying a total of $214,575.84 for 47,857 shares, this is the most they've acquired in one year. In 2018 Keith Michael Gottesdiener cashed out on 20,063 shares for a total of $513,210.00, their largest year based on trade value.

Loading...

Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

RHYTHM PHARMACEUTICALS, INC.

CEO & President
Updated Mar 11, 2020
Form 4
$6.14
$20.93K
Mar 11, 2020
766.13K
Options
Mar 09
Form 4
$6.14
$41.85K
Feb 12, 2020
765.57K
Options
Feb 10
Form 4
$4.59
$151.80K
Jan 10, 2020
631.12K
Options
Jan 08
Form 4
$4.59
$34.43K
Jul 17, 2019
631.12K
Options
Jul 16
Form 4
-1.99%
-10.29K
$30.09
-$309.65K
Mar 19, 2019
506.34K
Sale
ScheduledMar 15 - Mar 18
Form 4
-1.77%
-9.29K
$30.06
-$279.18K
Mar 15, 2019
516.63K
Sale
ScheduledMar 13 - Mar 14
Form 4
-0.46%
-2.45K
$30.04
-$73.57K
Feb 28, 2019
525.62K
Sale
ScheduledFeb 26 - Feb 27
Form 4
-2.39%
-12.92K
$30.02
-$387.89K
Feb 20, 2019
528.07K
Sale
ScheduledFeb 15 - Feb 19
Form 4
40.57%
221.07K
$30.00
-$118.02K
Feb 15, 2019
765.99K
Grant
ScheduledFeb 13
Form 4
-2.81%
-15.78K
$30.05
-$474.18K
Jan 24, 2019
544.92K
Sale
ScheduledJan 22 - Jan 23
Form 4
-1.77%
-10.12K
$30.01
-$303.55K
Jan 22, 2019
560.70K
Sale
ScheduledJan 18
Form 4
-0.12%
-662.00
$30.00
-$19.86K
Jan 17, 2019
570.81K
Sale
ScheduledJan 16
Form 4
-0.10%
-563.00
$30.00
-$16.89K
Dec 06, 2018
571.48K
Sale
ScheduledDec 03
Form 4
-2.80%
-16.50K
$30.08
-$496.32K
Nov 06, 2018
572.04K
Sale
ScheduledNov 02
Form 4
$4.59
$13.77K
May 10, 2018
713.32K
Options
May 09
Form 4
175.00K
Feb 16, 2018
175.00K
Grant
Feb 14
Form 4
Oct 10, 2017
585.54K
Options
Oct 10
Form 3
Oct 04, 2017
558.28K
Showing 18 results

INTERCEPT PHARMACEUTICALS, INC.

Investor
Updated Nov 13, 2023
Form 4
-100.00%
-83.38K
$19.00
-$623.77K
Nov 13, 2023
Disposition
Nov 08
Form 4
83.57%
20.66K
May 25, 2023
45.38K
Grant
May 24
Form 4
120.88%
20.53K
May 27, 2022
37.51K
Grant
May 25
Form 4
192.08%
19.12K
Jun 01, 2021
29.07K
Grant
May 27
Form 4
54.57%
4.56K
Jun 01, 2020
12.92K
Grant
May 28
Form 4
55.16%
3.74K
Jun 21, 2019
10.53K
Grant
Jun 20
Form 4
90.68%
4.54K
Jun 22, 2018
9.54K
Grant
Jun 20
Form 4
30.57%
1.17K
$64.00
$74.94K
Apr 09, 2018
5.00K
Purchase
Apr 09
Form 4
143.71%
3.46K
Jun 29, 2017
5.87K
Grant
Jun 27
Form 4
5.60K
Jul 21, 2016
5.60K
Grant
Jul 19
Form 3
Jul 21, 2016
Showing 11 results

Prime Medicine, Inc.

See Remarks
Updated Jun 07, 2024
Form 4
Jun 07, 2024
4.36M
Grant
Jun 05
Form 4
100.00K
Feb 27, 2024
100.00K
Grant
Feb 25
Form 4
-0.48%
-12.50K
Nov 14, 2023
4.36M
Grant
Nov 11
Form 4
497.74K
Apr 04, 2023
497.74K
Grant
Mar 31
Form 3
Oct 19, 2022
4.36M
Showing 5 results